Due to the low HER2-positive rate of mucinous carcinoma, NCCN guidelines[15] showed endocrine therapy for axillary lymph node negative, ER-positive, and/or PR-positive mucinous carcinoma. The gene discussed is ERBB2; the disease is mucinous adenocarcinoma.